Welcome to our dedicated page for XORTX Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on XORTX Therapeutics stock.
XORTX Therapeutics Inc. (NASDAQ: XRTX) is a bio-pharmaceutical company dedicated to developing and commercializing innovative therapies aimed at treating progressive kidney diseases worldwide. Headquartered in Calgary, Canada, XORTX focuses on addressing serious health conditions related to aberrant purine and uric acid metabolism, including diabetic nephropathy, polycystic kidney disease (PKD), and complications arising from diabetes and cardiovascular diseases.
The company has two lead programs targeting progressive kidney disease due to diabetes and PKD. Additionally, XORTX is actively involved in the development of uric acid-lowering agents to treat conditions like hypertension, insulin resistance, metabolic syndrome, and diabetes. Their pipeline includes xanthine oxidase inhibitors that show potential in managing diabetic nephropathy.
One of XORTX's strategic milestones is its alliance with Teijin Pharma Limited for the development of TMX-049, a promising xanthine oxidoreductase inhibitor. Another significant partnership is with the Icahn School of Medicine, focusing on studying acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.
XORTX Therapeutics Inc. is at the clinical-stage of biotechnology, aiming to identify, develop, and potentially commercialize therapies that can slow or reverse the progression of chronic kidney diseases. Their focus includes addressing the immediate needs of individuals facing acute kidney injury (AKI) due to respiratory virus infections and exploring other opportunities where their intellectual property can mitigate various health issues.
Rhea-AI Summary
XORTX Therapeutics Inc. announces the addition of Dr. Ronald Perrone to its Clinical Advisory Board, enhancing the expertise in treating autosomal dominant polycystic kidney disease (ADPKD). Dr. Perrone's vast experience in nephrology and clinical research will benefit the company's advanced clinical program, particularly the XRX-OXY-201 registration trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. reports significant progress in 2023, achieving key milestones in the development of therapies for kidney diseases. The Company received U.S. Orphan Drug Designation for the XRx-008 program for ADPKD, aligning endpoints for accelerated approval. XORTX made advancements in chemistry, manufacturing, and clinical studies, aiming to conduct a registration clinical trial in 2024. Notable achievements include FDA and EMA regulatory submissions, patent advancements, and organizational enhancements. The independent commercial assessment forecasts potential worldwide peak sales exceeding $1B annually for the XRx-008 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) announces the submission of a new patent for the treatment of chronic kidney disease, focusing on innovative therapies to treat progressive kidney disease. The patent outlines new formulations and methods for safer and more effective use of xanthine oxidase inhibitors (XOI) in the setting of CKD, including autosomal dominant polycystic kidney disease, diabetic nephropathy, IgA nephropathy, lupus nephritis, and focal segmental glomerulosclerosis. Positive topline results from the XRX-OXY-101 bridging pharmacokinetic clinical study reported substantial increases in the bioavailability of oxypurinol with the XORLO™ formulation platform, increased dose proportionality compared to non-formulated oxypurinol, and achieved therapeutic target values. These results will facilitate precise dosing recommendations for upcoming registration trials in individuals with progressing kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.18%
Tags
Rhea-AI Summary
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen. Mr. Treanor, a seasoned pharmaceutical industry executive, brings valuable experience to the Company. XORTX is preparing for the potentially pivotal Phase 3 study of XRx-008 in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) announces an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the Company to offer and sell common shares without par value with an aggregate offering price of up to US$3,701,931. The Company intends to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.74%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) has received a letter of compliance from Nasdaq regarding the minimum bid price requirement, leading to the curing of the deficiency. The company's common shares are now trading at or above US$1.00 per share for at least 10 consecutive trading days, resulting in the receipt of the compliance letter from Nasdaq. This development ensures that trading of the company's common shares on Nasdaq will continue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) announces the consolidation of its common shares on a 1:9 basis, with trading on the TSXV and Nasdaq to begin today. The consolidation is part of the Company's focus on developing therapies for progressive kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-88.89%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) announces the approval of consolidating its common shares on a one post-consolidation Share for every nine pre-consolidation Shares basis, effective November 9, 2023. The number of issued and outstanding Shares will be reduced from 17,989,687 to approximately 1,998,854. The Shares will continue to trade on the TSXV and the Nasdaq under the symbol XRTX on a post-Consolidation basis, under a new CUSIP number – 98420Q306.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
-
Rhea-AI Summary
XORTX Therapeutics Inc. announces new research findings on the role of uric acid in polycystic kidney disease and the potential of their proprietary formulation of oxypurinol as a treatment option. The studies show that moderate soluble uric acid can accelerate kidney expansion rate and worsen kidney function, and xanthine oxidase inhibition may be predictive of therapeutic benefit. The company plans to advance their formulation of oxypurinol in a clinical registration trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
Rhea-AI Summary
XORTX Therapeutics announces shareholder approval of share consolidation resolution to maintain NASDAQ listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.66%
Tags
FAQ
What is the current stock price of XORTX Therapeutics (XRTX)?
The current stock price of XORTX Therapeutics (XRTX) is $0.9716 as of January 22, 2025.
What is the market cap of XORTX Therapeutics (XRTX)?
The market cap of XORTX Therapeutics (XRTX) is approximately 3.2M.
What is XORTX Therapeutics Inc.?
XORTX Therapeutics Inc. is a bio-pharmaceutical company focused on developing and commercializing therapies to treat progressive kidney diseases worldwide.
What are the main diseases XORTX targets?
XORTX targets progressive kidney diseases such as diabetic nephropathy, polycystic kidney disease, and complications from diabetes and cardiovascular diseases.
Where is XORTX Therapeutics headquartered?
XORTX Therapeutics Inc. is headquartered in Calgary, Canada.
What is TMX-049?
TMX-049 is a xanthine oxidoreductase inhibitor being developed by XORTX in collaboration with Teijin Pharma Limited.
Who are XORTX's strategic partners?
XORTX has strategic partnerships with Teijin Pharma Limited and the Icahn School of Medicine.
What stage is XORTX Therapeutics in?
XORTX Therapeutics Inc. is a clinical-stage biotechnology company.
What health issues does XORTX aim to address?
XORTX aims to address health issues related to aberrant purine and uric acid metabolism, such as diabetic nephropathy, hypertension, insulin resistance, and metabolic syndrome.
What is the focus of XORTX's pipeline?
The focus of XORTX's pipeline includes developing therapies to slow or reverse chronic kidney diseases and addressing acute kidney injury due to respiratory virus infections.
What are xanthine oxidase inhibitors?
Xanthine oxidase inhibitors are a class of drugs that reduce uric acid production and are being developed by XORTX to manage conditions like diabetic nephropathy.
How does XORTX contribute to COVID-19 research?
XORTX collaborates with the Icahn School of Medicine to study acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.
XORTX Therapeutics Inc.